Test my supply
+2 more ↓
74%
Finnrick rating
#150 of 301 ranked vendors
220 of 273 classifiable tests passed
methodology · Purity focus
Finnrick analysis

ZLZ Peptide shows its strongest purity-focus evidence in Retatrutide and Tirzepatide, with GHK-Cu also mostly passing, but the record is dispersed rather than uniformly clean. TB-500, Tesamorelin, and BPC-157 carry the weaker signals from repeated purity or fill misses; recent results often improve, while uneven or absent batch IDs limit traceability.

methodology →
vendor intelligence report
Vendor Intelligence Report: ZLZ Peptide

Corporate and B2B records trace ZLZ’s storefront to a Hunan chemical-intermediate operator with BMK/PMK precursor listings. The report also maps altered-COA allegations, alias-led sales channels, irreversible payment rails, and lookalike-domain risk.

30 pages7 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutide
$0.68
91%
102
2
Tirzepatide
$0.42
86%
93
3
GHK-Cu
$0.07
84%
17
6
Sermorelin
$1.52
56%
5
7
BPC-157
$0.68
48%
13
8
CJC-1295
-
46%
5
9
Tesamorelin
$2.00
37%
16
10
TB-500
$1.76
36%
6
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%28 Apr 2026: 73%5 May 2026: 73%5 May 2026: 73%6 May 2026: 73%6 May 2026: 73%6 May 2026: 73%6 May 2026: 73%8 May 2026: 73%11 May 2026: 73%11 May 2026: 73%13 May 2026: 74%13 May 2026: 73%13 May 2026: 73%13 May 2026: 74%20 May 2026: 74%12 Jun 2026: 74%15 Jun 2026: 74%15 Jun 2026: 74%15 Jun 2026: 74%24 Jun 2026: 74%24 Jun 2026: 74%24 Jun 2026: 74%24 Jun 2026: 74%26 Jun 2026: 74%1 Jul 2026: 74%1 Jul 2026: 74%1 Jul 2026: 74%10 Jul 2026: 74%10 Jul 2026: 74%13 Jul 2026: 74%15 Jul 2026: 74%15 Jul 2026: 75%15 Jul 2026: 75%15 Jul 2026: 74%23 Jul 2026: 74%23 Jul 2026: 74%23 Jul 2026: 74%5 Aug 2026: 74%5 Aug 2026: 74%5 Aug 2026: 74%10 Aug 2026: current 74%73%74%74%Apr 26Aug 26
Test my supply
ZLZ Peptide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
5 Aug 2026Pass
Retatrutide
lab nameView COA
5 Aug 2026Pass
Tirzepatide
lab nameView COA
5 Aug 2026Pass
Retatrutide
lab nameView COA
23 Jul 2026Fail
Tesamorelin
lab nameView COA
23 Jul 2026Pass
BPC-157
lab nameView COA
23 Jul 2026Pass
GHK-Cu
lab nameView COA
15 Jul 2026Pass
Sermorelin
lab nameView COA
15 Jul 2026Pass
TB-500
lab nameView COA
15 Jul 2026Fail
GHK-Cu
lab nameView COA
15 Jul 2026Fail
BPC-157
lab nameView COA
1-10 of 200

About ZLZ Peptide test results from Finnrick

ZLZ Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 10 peptides and 274 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible ZLZ Peptide peptides in this dataset are Retatrutide (102 tests) and CJC-1295 (5 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.
Test my supply